07:41 AM EDT, 04/08/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Tuesday its namesake unit has licensed commercialization rights for the sebetralstat experimental treatment for hereditary angioedema in Japan to Kaken Pharmaceutical.

The company will receive an upfront payment of $11 million, with an additional payment of up to $11 million, subject to a regulatory milestone expected early next year. KalVista said it's also eligible for commercial milestone payments, plus certain sale royalties.

Hereditary angioedema is a disorder that leads to recurrent attacks of severe swelling.

KalVista shares were up 3.5% in recent premarket activity.